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CHAPTER I 
Introduction 
In most hospitals today, plastic devices are replacing 
the traditional metal, glass and rubber . The increased use 
of polymeric mate rials as implant ed prosthetic devices, 
catheters, disposable equipment and for the adminj_stration 
of blood , intravenous fl uids and drugs has been widely ac-
cepted by the medical profession. 
Large volume pare nteral solutions have be e n available 
in p : astic bag containers since 1971. The plastic bag func-
tions physically by the force of gravity ;.tnd atmospher ic pres-
sure . As the fluid l eaves the container, the bag collaspses 
since it is not vented. Without this venting, there is a 
reduction in the possibility of airborne contamination and, 
also, the possibility of air embolism is reduced. In addition, 
tlle plastic container has offered the advantages of r e duction 
in breakage , economy in space during storage, simplified 
disposal and r eduction in weight (1) . 
It has bee n suggest e d (2) that the ideal plastic con-
tainer for storo.ge and administra tion of large-volume paren-
te:ta.l~-> ·~;hould: 
1 
(1) allow for the visual inspection of t h e paren-
teral solution prior to administration 
(2) be chemically inert 
(3) b e fre e of particulate matt e r 
(4) not interact with the solution or additive 
(5) prevent the loss of fluid through the wall 
of the container 
2 
(6) maintain the steri lity prior to and during the 
administrRtion of the pare nteral solution. 
With the increase d use of plastic containers for paren-
teral solutions and drugs, studies have looke d at some pos-
sib le incompatibilities that may exist between the parentera l 
solution, drug , and container. 
The significance of the j_ncompat ibi li ties bctw0en plas--
tics and drugs in pharmaceutical systems was reported by 
John Autian in the l ate 1950's. Aut ian· classified the drug 
plastic interactions under four categories . These four head-
ings are still useful t oday in classifying the potential 
interactions which might occur upon contact with the paren~ 
teral solution, drug , a nd container (3) . 
Th e four categories are : 
(1) Leachin_K - de fin e d a s the loss of a constitue nt 
of the plastic to the imme diate solut ion . The 
rate of leaching will be dependent on the type 
of solutio n, drug, pH, contact time a nd t empera-
ture. 
3 
(2) Chemical Reactivit y - define d as the chemical 
interactions which alter the properties of the 
plastic as a r esult of contact of the plastic 
with the solution. 
(3) Pe rmeat ion - defined as the ability of the solu-
tion vapor or liquid to pass throu gh the conta ine r 
o r the passage of e nvironmental gases into the 
solution wit h i n the container . 
( 4) Sorptior~ - defi ne d as the loss of product compone nts 
to the plastic con tainer , include s both adsorption 
and absorption. 
Much of the early work with chemical reactivity h as 
bee n with disposable sy~inges and n eedles. It was felt (4) 
that the increased use of disposable syrin gc~s and needl es 
would be b e neficial to the patient because of : 
(1) r e duced d i scomfort to the patient by insuring 
s harp needl es for inj e ction 
(2) needles would on l y be u sed once , thereby de-
creasing the c hancei of cross-infection 
(3) the conven i ence of administration 
(4) decreasing cos ts by e limi nat i ng t he c l eaning a nd 
s terilizat ion o f equipment and supp l ies . 
Alterations of the or iginal proper t ies of the plastic 
syringe as a r esul t of cont act with the product affects the 
proLecti ve and storage capacity of the plast ic container. 
Autian and Brewer (5) studied the compatibility of 
plastic-hubbed needl es using 126 offj c ial (USP and NF ) and 
4 
6 0 non--o fficial par e ntera l products. A major problem that 
was o bserved with all the plastic hubbed needles was the 
destruction o f the plastic hubs by erythromycin intra-
muscular injection . It was found that t he des truction was 
due to t he solvent, diethyl carbonate , contained within the 
parenteral solution. 
Auti a n and Dhorda (4) fol l owed with a study of plastic 
disposa ble syrin ges and their compatibility with par ent e ral 
products. They s tudied the effects of 129 official a nd 62 
no n-official in j ectable sol utio ns i n plas ti c syringes com-
posed of nyJ.on, polystyren e , and polye thylene . Their results 
indicated that paraldehyde, benzyl alcohol, b enzaldehyde a nd 
b e n zyl b 8nzoate dissolved po lystyrene bnt b.ad no ef feet on 
the nylon or polyethylenE-) syr inges after G ho·J.:cs of contaet 
time . Dimercaprol injection , after 12 hours o f contact time, 
s howe d etching and c l ouding of the intejnal s urface of the 
polystyrene syringe but no e ffect on the nylon or polyethylene 
syringes. 
In a l ater st udy , Stanasze k and Pan (6) i nvestigated 
the compat ibil i ty of prefilling glass and plas tic syringes 
with hydroxyzine hydroc hloride, meperi dine h ydrochlori de 
and atropi n e s ul fa t e for l ater u se in treatment areas within 
a hospital . Comparisons between glass and pl as t ic were made 
over a t e n rtay period . Resul ts s h owed that there we r e 
ne i t her visual signs of degradation of the p last i c syringe 
nor c ha nges in the appearance of any c on s titue nt s i n any of 
the admixture systems . It was report e d that the pre-filling 
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of syringes was feas ible for these drugs but the res ults 
should not be projected to other drug combinations unless 
teste d for compatibility. 
PERMEATION 
Excessive loss or gain of water, oxygen or volatile 
organic compounds can cause de terioration of the product 
contained within the plas tic container. Early s tudies (7,8) 
have s hown the loss of f luid through polyvinyl chloride (PVC) 
and polyethylene blood bags and the need for an outer pro-
t e ct ive envelope to prevent fluid loss . 
Edelman and co-workers (9) looke d at the stabil ity of 
ni troglycerin tablets stored in various plast ic containers. 
0 Results s howed t he p ercent loss of nitroglycerin a t 25 C and 
50°C . Whe n stored in polystyre n e containers the l oss , 13 . 3% 
at 50°C and 3 . 1% at 25°C, was g r eater tha n the loss, 2 .2% a t 
50°C and 0.0% at 25°C, in g l ass containers. All results were 
take n after storage in the containers for 21 days. It was 
con c l ud e d from the study that nitrog l ycerin s hould not be 
s t o r e d or di spensed in containers other than glass . 
Brennan and co-workers (10) evaluate d the moist ure per-
meabil:Lty of 13 different plastic and g l ass prescription co11-- · 
tainers. The results co1tclude d that the glass vials o ff ered 
the best prote ction agains t moisture pena tration. The l east 
effective container was the po lys t yrene via l . The mos t e f-
fective plast i c contai ner was the h igh-dens ity polyethylene 
container . It was pointe d out t hat the resistance t o mo i s tur e 
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vapor p enetration included both the permeabil ity of the con-
tainer material and the design of the closure. 
Trueman (11) report e d that the fluid loss at room t e m-
perature, from intravenous solutions and perito neal di a lysis 
fluids stored in plastic intrave nous infusion packs could 
range from 0.96-2.56% per year. The concentration of 
solution in the c o ntaine r would have been outside the l i mits 
of the British Ph ar~acope ial standards within two years a f t e r 
manufacture. Also , }.iacDonald ( 12 ) exami ned t he permeabi lity 
of PVC from three manufacturers and that of polypropy l e ne. 
Results showed that the polypropyl ene bag offered a better 
protective barrier than the PVC bags. Without the outer pro-
tective wrapper, PVC lost 1.6-4% of its volume when stor e d 
at 25°C a fter 12 months compared to a loss of 1% with the 
polypropylene b ags . Currently , t he u se of an out e r e!lvclope 
is u sed with marketing of PVC intravenou s flu id containers 
to decrease soluti on vapor loss. 
SORPTION 
Due to the v a riety of polymeric s ubsta.nces that are 
used in the ma nufac ture of containers, there ex i sts the pos-
sibility that sorption might occur betwee n drugs possessin g 
certain chemical properties. The resul tant sorption ( adsorp-
tion and/ or absorption) that couid occur would result in a 
d e c re a se in the therapeutic concentration delivered to the 
patient. 
Sorption was s hown to occur in pharmaceutical systems 
'1 
by .1\uU.an ( 5) in the early 19GO' s . His studies s howed clear ly 
the sorption that occurred when diffe rent conce ntrations of 
drug solutions were placed in the barrel of nylon syringes. 
The following table (5) summari zes the amount of drug bound 
by the nylon syringes. 
Agents Bound by Nylon Syringes 
(Expresse d aspercent after one wee k of contact ) 
4-chloro-- 3-met hylphenol 
propylparaben 
salicylic acid 
parahydroxybenzoic acid 
methylparaben 
b e nzoic acid 
pheno l 
p-aminobenzoic acid 
sorbic acid 
m-hydroxybenzoic acid 
85.5% 
85 . 1 
80.1 
78.7 
75 . 5 
67.1 
60 . 5 
51.0 
47.0 
39.5 
The poss ible sorption characteristics of 17 d r u gs was 
r eporte d by l;Ioorha tch and Chiou ( 1 3) usin g GOJ:Jmercic:d PVC 
hags used for IV solutions . Using spectrophotometric methods, 
three of the drugs, vitamin A acetate, sodium warfarin , and 
sodium methohex ital were fou nd to b e sorbed by the plastic 
strips. They concluded in their resu lt s that the sorption 
of th e drugs to the plastic was increased by factors such as 
drug concentration, temperature, and time . Because t he amount 
of drug sorbed increased with time, they suggested that the 
sorption was due to absorption by diffusion through the p l astic 
rather than adsorption on t h e surface of the plastic. 
IIirsch and co-workers (14) examined the extent of in s ulin 
sorption to the s urfaces of PVC intrave nous delivery systems 
using a radiotracer technique. Their r esult s indicat ed that 
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there was gr eate r sorpt ion of insulin from solutions of normal 
sa line as compar ed to soluti o ns in 5% dextrose in water . 
Also, t hey found that significant binding occurre d whe n using 
l ow concentrations of ins ulin . They considered t hi s to be 
clinically significant since one must consider the binding 
effects if adequate insulin is to be delivered to a n ind ividu a l 
whe n using low concentrations of insulin . 
In a follov.- up to Hirsch ' s work, Whalen e!__al . ( 15) 
studied the availability of low- dose insuli n from intra-
venous admixture systems . A comparison of the availabilit y 
of ins ulin from glass and PVC container systems did not show 
a sta tistically significant difference . This r esult differed 
from other studies i n which it was suggest(}d tbat PVC con-
t ainers bind mor e i nsulin than g lass systems . 
Sture k e!:__~!:_ . (16) studie d the stablU.ty of nitrogl ycerin 
injection by gas chromatography . Their· results showed that 
the loss of nitroglycerin over a 50-hour period was 13 .1% 
from g l ass and 8 3 . 5% from 1 50-ml Viaflex bags . Both t he 
bottle and bag contained 100 ml of a 0 . 47 mg jml solution. 
They reported that the loss was a non-linear process similar 
to the sorption r epor ted by Moorhatch and Chiou (13) . Their 
recommendation was that n itrogl ycerin soluU.ons sho uld not 
be infused from Viafl ex containers. 
Recently, Parker and h is co-workers ( 17 ) s tudied ·the 
compatibility of diazepam i n PVC. Their r esu l ts reported 
that 30 minutes followi ng the preparation of a 10 mg/102 ml 
solution, in IV infusion fluids , the diazepam concentration 
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ranged from 62 . 1% to 71.1% of initial concentration. They 
further reported t h at the percentage of diazepam lost from 
the solution appeared to be a function of both the drug con-
centration and time. The hi ghe r the drug concentration and 
the longer the drug was kept in contact with the container , 
the greater the amount of diazep am which was r emoved from 
solution . Controls using glass containers did not show 
any significant changes in drug concentration over the same 
period of time and at the same drug concentration . 
LEACHING 
A major concern with the use of plastic containers is 
the possibility of leaching of constituents from the plastic 
container. 
· On e of the most widely used plastics in medical applica-
tions is PVC. PVC is used to collect, ~tore, and trans port 
blood, infuse drug solutions, collect urine , catheterize 
parts of the body, and many more applications too numerous 
to itemize . 
In order for PVC to have varierl physical properties , it 
i s necessary to add many additives to the formulation. Plas-
tic:lzers , stabilizers , colorants, and other agents are 
added to the formulation to confer its specj.a l properties. 
These chemical agents are subjected to heat and press ure to 
form the finished product . It is the variety of chemical s , 
heat, and pressure which present a potential problem in the 
use of PVC plastics (1.8, 19). 
10 
The softness and flexibility required for the use of 
PVC plastics in large-vol ume parenterals can be achieved by 
the addition of phthalate plasticizers (20). The most widely 
u sed phthalate plasticizer for PVC medical devices is di-2-
ethylhexyl phthalate (DEHP). This plasticizer is added 
during the manufacturing process and may account for 20-40% 
of the finished weight of the plastic product. The amount 
of plasticizer present in the finished product will determine 
the c larity and flexibility of the PVC bag (21, 22). 
In addition to the PVC plastics u sed in the me dical 
profession, there is some use of non-PVC polymers. These 
non-PVC polymers offer a higher tensile strength and rigidity 
than th e usual PVC forrr.ula t :Lons. They ::c:2 of sueh physical 
properties that they may be formed into devices without the 
addition of significant amounts of plasticizers, stabilizers, 
or other materials . 
Since in the pharmaceutical industry, the largest use 
of plastics is for contain~~rs, j_t is i mpor tant tha·t the 
plastic used b e adaptable to a container that is s trong, rigid, 
transparent, and which does not interact with the drug con-
. tained within. There are several classes of polymeric 
materials such as nylon, polyethylenes a nd polypropylenes 
which offer some hope as future containers . The physical 
properties of these plastics are almost ideal for use in 
l arge volume parenteral containers. They are rigid polymers 
whi c h contain less mat erial that could l each from the con-
t ai n er. Except for the problems of transparency , these 
ll 
types of plastics present fewer toxico l ogica l problems (21 ). 
Marcel and Noe l (23) reported what they thought to be 
DEHP contamination of blood stor e d in comme~cial tra nsfusion 
p eaks . Analysis was made using infrared spect r ophotome try 
a nd gas-l iquid c hromatography . Aft e r a period o£ storage 
for 21 days in the blood bags, the blood s howed amo unt s 
of DEHP of 11.5 mg/100 ml o£ blood. Thei r results indicated 
that the concentrat j_o n of DEHP inc r eased as a function of 
time storage. In a follow up to this r epo r t , Gesler and 
Kartinos (24) stated that the plasticizer u sed in the PVC 
b ags was DEHP as determine d by thin layer and gas chroma-
tography . They further stated tha t t he amounts o f plasticizer 
present i n the bags were well b e low the level.s required to 
cau se any t oxicity problems when infused . 
J aeger a nd Rubin (25) found DEHP in concentrations of 
5 t o 7 mg /100 ml of human blood stored in PVC blood bags 
for 21 days . They also po inte d out t hat DEHP accumulate d 
in r at livers after p e r f u sion a nd in t h e human spleen a nd 
abdomina l adipose tissue afte r b lood trausfusions . l"urt her-
mor e , in another report, Jaeger and Rubin ( 26 ) re j ected 
the corit e ntion that phthalate plasticizers, as found in 
biological f lui d s such as blood, are safe . 
Moorhatch a nd Chiou ( 27) s tudi e d the effect of storing 
various solutio ns in commercial PVC bags. Sodium c hlor ide in-
j ection, di s till ed wat e r, 5% dextrose inj ection, 5% e thanol 
in water, and buffe r solutions with pH's rangi ng from 3.5 
12 
to 9.5 were stored in PVC bags for a period of 18 hours . The 
ultraviolet absorbance of the solutions indicated insignifi-
cant leaching of UV-absorbing materials . However, PVC bags 
containlng solutions of Tween 20 and Tween 80 showed hi g h UV 
absorbance indicating the leaching of a chemical or chemicals 
from the PVC bag. It was found that Tween 80 seemed to cause 
more leaching than Twee n 20 . Although no attempt was made 
to isolate or identify the leache d components, a comparison 
was made between the UV absorbance spectra of Tween 20 solu-
tions stored in PVC bags for 48 hours and DEHP . Due to the 
similarity between the absorption spectra, i t was concluded 
that the leached component was DEHP or some other related 
phthalate plasticizer. 
Stokes and co- workers (28) looked at t he addition of 
aminophylline, lidocaine, and metaraminol bitartar~te to 
0.9% sodiUm chloride injection in glass· an d PVC containers . 
The ir results s howed that the differences in handling and 
storage conditions influenced the quant ity of particles that 
were found in the pl astic containers . They suggested that 
the amount of particulate matt e r produced could be reduced 
if, after . transport. or shipment , the bags were stored for a 
period of two or three months under quie t conditions . At no 
time in the s tudy was there a n attempt to identify the part-
icles found in the bags. 
Whitlow ( 29 ) had shown that particulate matter could 
be produce d in plastic containers by cont i nuous shaking . In 
13 
an earlier study , Needham and Luzzi (30) ide ntified the 
particles as the plasticizer, DEHP. Subsequent correspon-
dence by Darby and Aussman (31) r egarding Needham and Luzzi's 
finding report e d that the containers had very low particu-
late count s before shaking. Severe shaking generated micro-
spheres of liquid plasticize r, 0 .1 ppm, which is less than 
the 5 ppm d escribed in the package insert that accompanies 
the Viaflex containers. 
Corley and co-workers (32) looked at the effects of 
administration time, hydrogen--ion concentrcttion, ethanol con-
tent, and a g itation on the amount of DEllP found in PVC bags . 
Solutions of 0.9% sodium chloride injection, 5% dextrose in-
jectiorl, sodium lactate inj ection and steril e water for irri-
gat ion wer0 stored in PVC bags. Length of administration 
time and h ydrogen-ion concentration had no effect on the 
.amount of DEHP leached .f:co~n the plastic · PVC b ags . Agitation 
of the PVC bags ~ith the solutions increased t he amount of 
DEHP detect ed as compared with non-agitated bags . : rt was 
s l1own that the concentration of et hanol was the det ermining 
factor in the amount of DEHP l each ed from the PVC bags. 
'I'hey GGnclude d from thei r study that the pharmacis t could 
lower the amount of plas ticizer j.n the PVC bags by storing 
the newly transported containers for a period of one or two 
mont hs to allow the DEIH> particles to settle. Whe n using 
solutions , it i s r e comn:E·nded that 0. 9% sodium chloride inj ec-
tion or Ring e rs inj ec~ion be used since both of t h ese so lu-
tions leac he d l ess amount s of DEIIP . Also, the use of caution 
1·1 
when mixing additives , using minimum agitation and avoiding 
the use of ethanol within the plastic containers would lower 
runounts of DEHP . 
With the concern of the presence of a leachable con-
stituent, DEHP, from the PVC containers, studies were begun 
o n toxicity of DEHP . Several (33-39) have reviewed the tox-
icity and health threats of phthalate esters present in PVC 
containers. These reports diffe r on the possible health 
t hreats that exist with the use of phthalate ester s as plas-
ticizers. Autian (22) reported that the or al and paren t eral 
toxicity from DEHP was of a l ow order . The LD50 values in 
animals ranged f r om 14.2 gmjkg in mice to greater than 50 
gmjkg in rats. J aeger and Rubin (40) found that the organs 
of two patie nts, who had received l arge volt~es of blood 
f r om DEID? plasticized containers, contaiut~d large amounts of 
DEHP. The compound was found in the liver, lung, spleen and 
a bdominal fat in concentrat ions ranging from 25 mcgjgm in the 
spl een to 270 mcgjgm in abdominal fat . Because the r e was no 
current avail able information on wha t ex::tct t oxicological haz-
ards exist, they recomr.1c nded t he deve l opment of plas tic form-
ulatio ns which would not contain leachable mat erials . 
In experiments p erformed by Dr . DeHaan (10), it was 
found that DEHP l eve l s of 4 mcgj~l (a l eve l obt a i ned with huma n 
blood stored in PVC blood bags after 1-2 d ays ) resu lte d in 
comp lete loss of f unction i n beating chick embryo heart cells 
in tissue culture medi a . \Vi thin 24 ho urs , 97-- 98% of the 
cells maintain e d in the culture media were killed . 
Recently , Jacobson ~~~-~t_!_ . ( 12) studied the ef ·Eects o:f 
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DEHP that was leached was from PVC blood bags on h epatic 
function and histology in the rhesus monkey undergoing c hronic 
transfusions. The average amount of DEHP infused in one year 
was 69.3 mg or 21.3 mgjkg . This compares to t he amount of 
DEHP received by patients who were receiving chronic trans-
fusions over the same period of time. Four of the seven PVC--
transfuse d monkeys had abnormal 99mTc live r-spleen ratios, 
four of the seven demons trate d abnormal 13SP clearance and 
six of the seven had abnormal liver histopathology upon com-
pletion of tronsfusion therapy. Non-transfused monkeys and 
those transfused with platelets processed in polyethylene 
containers were normal. 
Toxicity studies done on other plast ic polymer containers 
has bee n encourag ing. Guess and Raberma11 (43) democs trated 
the lack of tox icity b y t hree rigid plas·tics ( po lyc ar bonate, 
polyethylene, and polypropylene) whe n e·valuat<~d a·s finis h ed 
products. Howeve r, it was shown that alcohol extracts of 
the p l astics did elici·t evidence of toxicity, e . g . ; eosinophilia . 
Data indicated t hat as the percent of additives ( extractablcs) 
increased, the incidence of toxicity increased. Their general 
c onclusions were that the fewer additives contained in a 
polymer, the fewer problems with that plastic container or 
products. 
The preceding studies h ave shown t h e ex i s tence of prob-
lems with the use of plasticize d containers for tl1e adminis-
tration of pare nteral solutions , and the need to develop new 
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types of plas tic container s for use in large volume parentcrals . 
Studies have shown that there are othe r types of polymeric 
materials, polypropylene and polyethylene, which have the 
potential for use as containers for large volume parent e ral 
solutions. Studies have also indicat ed that these plastic 
mat e ri a ls l ack the toxicity associated with the use of PVC 
plas tics . 
This present s tudy was designed t o evalua te d ifferent 
types of plastics for potential use as large volwne parenteral 
containers. Usin g several diff erent therapeutic agents, 
a variety of plast i c containers was exami ned fo r t he pos-
sibility of the occurrence of drug-plast ic i nteract ions . The 
inclusion in the study of a coMnercially hvailable pJ.astic ized 
product us e d for t he admi ni stration of po.r ent e ral solutions 
was to compare the rcsnl ts of commercial product ~:; to non·-
commercial products . 
CHAPTF.U I I 
Experime ntal 
The purpose of this experimental work was to evalu ate 
different plastic containers for potential use as l arge 
volume parentera l containers replacing the c urrent PVC con-
tainers . Eo.ch of the d r ug solutions were examined u sing 
spectrophotometric analysis and microbiological assay t o 
determine the presence of any drug-plastic interactions as 
discu ssed i n Chapter I . 
The solutions used in this study were prepared in 5% 
dextrose injection . a It was selected as a veh iclo because 
of its wide usage in intravenous admixtures for administering 
drugs . 
'l'he drugs chosen for this study are l isted in Table l. 
In order to simul ate the actual cond itions, the concentra-
tions were sel e cted to resembl e those 11sed in clin i cal prac-
tice, i.e. those considered t o be normal doses for an average 
adult of 70 kg , as r ecommended by the literature and manufac-
turers' product information . 
The containers used for this study are listed in Table 2. 
Prior to u se, a ll containers were wa~hed 3 times with sterile 
water to remove any foreign material which might interact with 
aCutter Laboratories, Berkeley , CA 9~710 . 
1'1 
1 __ --l---- TABLE 1 
GENERIC NM1E, TRADE NAliE , MA.i'JUFACTURER, THERAPETL:IC CONCENTRA.TION, 
SCANNING CONCEi'JTRATION, AND A l1.A.X OF DRUGS STUDIED 
Trade Name, The~apeutic Scanning 
Ge:1e:-r-i c Manufacturer Concentration Concer..tration 
Vitamin A Palmitate Aquasol A 
usv 150 r:1cg/ml 1 mcg/r:1l 
Tuchahoe , ~~ 10707 
Floxuridine FUDR 
Roche Labs 70 mcg/ml 20 mcg/rrJ. 
Nutley, NJ 07110 
Methyldopate HCl Aldomet 
MSD 5 mg/ml 10 mcg/ml 
West Point, PA 19486 
Gentamicin Sulfate Garamycin 
Schering Corp . 0 . 8 mg/ml 80 mcg/ml 
Kenilworth, NJ 07033 
Cephalothin Sodium Keflin 
Eli Lilly 10 mg/ml 20 mcg/ ml 
Indianapolis , I N 46206 
Hethot"t""exate Lederle !.abs 
Pearl River , NY 250 !!leg/ rrJ. 8 n:cg/ml 
10965 
Dopamine HCl I n::ropir. 
Arnar- Stone Labs 0 . 4 mg/al 16 mcg/ml 
Aqu.sdilla, PR 00604 
A Max 
285 run 
269 nm 
282 nm 
257 nm 
241 nm 
304 !'.In 
283 nm 
,..... 
00 
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TABLE 2 
EXPERINENTAL CONTAINERS 
Lm..r Dens~lty Polyethylene (LDPE) -· 4 oz., (Nanufactured by \Vhea ton Pl as tics, 
obtained from Con t ainer Service , 
Hayward , CA. 94545 ) 
l~_:!:_gh De nsity Polye thylene (HDPE) -· 4 oz., 
J..9LY~.~.nyl chloride (PVC- N) - L• oz., 
Polymethyl pentene (P1-1P) ·- '• oz. , 
II II 
II II 
II II 
II 
" 
(Obtain~d from Nalgene Co., 
Rochester, NY 14602) 
II II 
II II 
II II 
Gl.ass (control) - 125 Pyrex conical flask (Corning Glass Works , 
Sa nta Clara, CA. 95050) 
Pojy_~inyl ch lorid e (PVC-V) ·- Er.:pty Via flex 250-mJ. bags (Travencl L ::~ bo r.n­
t or i es·, Inc., Union City, CA 
%587) 
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the study. The containers were selected for use on the 
bas is of low amounts of leachable constituents and potential 
use as large volume parenteral containers. Table 3 lists 
the comparative properties of the plast ic containers use d in 
the study. 
A Bausch and Lomb Spectronic 600 Double Beam Spectro-
photmetrica linked with an OmniScribe Series B-5000 Strip 
Chart Recorderb was used for spectroscopy examination . A 
deuterium lamp provided an incident wave length of 220 to 350 
nm. The solutions were analyzed in Pe rkin-Elmer 30-300 Silica 
Cuvetsc for the scanning procedures. 
To obtain a standard specturm, suitable concentrations 
of the drugs were needed for U.V. scannin g . Individual dr ug 
sol utions were diluted w:l th 5% dextrose Lljection and then 
scanned in comparison to a r eference solution of 5% dextrose 
injection. Dilutions were prepared and· sca111ied until a maxi-
mum absorbance of 2~9 was obtained on the recorder pape1'. 
Although all t he so lutions were made at the rapeutic concen-
trations, it was necessary to dilute them before scanning . 
This was to provide a concentration which could be scanned 
by the spectrophotometer . Once the U.V . spectra measured the 
optimum absorbance , the Beer ' s Law plots were plotl e d to r 
-----~--~ 
a Bausch and Lomb Optical Company, Rochester , N.Y., 14602 . 
bHouston Instrument, AustJ.n, TX., 78753 . 
cColeman Instruments Division, Ma ywood , IL., 60153. 
I ··- - r· • 
1f..BLE : 3 
CO:,:PP.RATIVE ?RO?ERTIES OF CCNTA!NER 1-'ArERiALS* 
LEACHAaLE !•!1\TER G;.s (o2) ~'.ATE RIAL STRUCTURAL U:-l!T AVERAGE AUTO- i\DDITI'IES CONSTITU- VJlPOR PERME-
~-DfNSliY___\:..lAVABLE_PRESENL_.ENTS PE RME.'\U_ON ... ATiON. __ 
POLY ETHY LENE 
- LW DE~:S ITY (- CH2- CH2-)n 0.92 NO LOW LOW HIGH 
- HIGH DENSITY ( - CH 2- cH2- )n 0.96 YES LO\·! W4 ·LOW 
POLY!>RCPYLENE (-CHCH3-CH2-)n 0.90 YEs · LOW LO\~ i•iODERATE 
?OLY 'nt;YL CHLORIDE 
- FLEXISLE ( - CHCl - CH2- )n 1.2 v::s HIGH HIGH H! G!i 
- F:IGID ( - CHC1- CH2- )n 1.4 YES Lot~ LO~! HIGH 
PCL ':'CAR130NATE (~a-c6H5-C(CH3 ; 2-c6H5-co2- )n 1.2 YES . LOW LC'.-1 H!Gf! 
PCL YSTY RENE (-CH(C6H5) - CH2-)n 1.05 NO . LQ;-! W·J HIGH 
#?CL. Y ii.EiriY LPENENE ( - CH 
CH2 -CH2- )n 0, 83 YES L0\·1 !..0\-1 MODEAATE \. 
CH 
/"\. CH3 CH3 
0 0 
GLASS 
I I 
0- Si - 0- Si - U 2.23 YES LOW L0\·1 NONE 
I I 
0 0 
"'Se-:-g:n3n, D.H.: In::ompatib1_1itics in Large '!o1urr:e P3renterals , D~ug !nte11 . 1!:359 (J :.:ne) 1977 
~:?ersonal Co:rrnunication, Na1ge Compor~·. ::-~·.-•sion of Sybror: Corp., ~oc:,ester, N.Y. 1 ~602 
LOW 
LOW 
LOW 
W ·i 
LOH 
LC\o/ 
H!GH 
LOl·i· 
NONE 
POTENTIAL 
REACT I DN/l~ PHYSICAL 
PRODUCI PRO?E.iHIES 
LOH TRANSLUCENT. 
FLEY.I BLE 
LOW TR.~~~S!_ t;CEi~T , 
SEtH - RIG I D 
LO~I TRM1SL!.!CENT. 
Se·!l- P.I GI D 
t·:OD TRf,t/SPARErH. 
FLEXIBLE 
LOW TRJI:iSPARENT, 
RIGID 
LOt</ TRA:;SPARENT ~ 
RIGID 
/100 TRI,i/SPAReH , 
RIGID 
LOW TRANSPARENT • 
RlGIU 
LOW O?fiCALLY CLEAR, 
RIGID 
!:\:) 
f-1 
22 
each of the drug solutions. 
Following the preliminary investigation, triplicate 50 ml 
sample solutions were placed in each of the plastic con-
tainers selected for the study. A 50 ml Pyrex conical flask 
was used to serve as the control for the e xperime nt. The 
containers we re stored under normal light and room temperature 
conditions . Aliquots were examined at intervals of 0, 1, 12, 
and 24 hours after the solutions were placed in eac h of the 
containers. The reference solution contained 5% dextrose 
injection, excluding the drug being scanned, when the so lu-
tions we re placed in the cuvets for examination. 
Detection of the presence of a drug-plastic interaction 
wr;.:s made by compar lng the standard spectr11m of tho fJ :;:ug ;:uJd 
the f.~pectrum obtained at e ach t:ime int erva l. The spc-)etrum 
at each time :lnt erval was compn,red to tll•:= spec trurr. obtain8d 
from the gl ass conta i ner. Any changes in the spectrum might 
indicate the presence of a drug-plastic interaction as evidenced 
by changes in the peak h e ight, s hift or altern tion t in the 
Amax, o r the developme nt of seco ndary peaks . An increase in 
t he ~max could indicate the loss of fluid or permeation, or 
the leaching of constituents from the plastic contain e r. 
Secondary peaks or a shift in the Amax might indicate the 
presence of a leachable compound from the plastic contain er 
or a c hemica l interaction causing a change in the drug within 
the container. A decrease in the Amax could ha.ve indica t e d 
sorption of the drug to the plas tic container and a decrease 
in t he therapeutic conce ntration of the active drug . 
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Microbiological Assay 
To determine the loss of potency of t h e antibiotic sol u-
tions used in the study, microbiolog ical a ssay wa s perf ormed 
in addition to the spectrophotometric analysis. A reduction 
in antimicro bial activity will manifest it self as a r e duction 
in the diameters of the zone of inhibit ion . 
The procedure , outlined in U . S.P . XIX (14), was modified 
by the methods of Bauer, et __ al . ( 45) ancl Grove and Randall 
( 46). I nste ad o f using agar c ups, s t eril e a bsorbe nt pape r 
:1
. a 
r lSCS , one-half inch in diame ter we r e used in thi s study. 
All ma terials use d we r e s t e rilized b e for e use . 
kno wn to be s e n s i U .ve to c e phalothin and .§ __ ~~J~I~.£}_0_s;_occu~ 
~_p:Ld~..:~rr~!dis, A. T. C. C. /)12228, s e ns i t J v e t o gentaiili c in were 
chos en to verify the antimicrobial activity . The cultures 
were maintained on agar slants consisting o f Bact o Anti-
biotic Media #lb and we re transferre d wee kly . Fre shly in-
noculated s l a nt s we re incubat e d at 37°C for 24 h o urs to 
promote a d e quat e g rowth and the n re f rigera t e d. 
Twenty-four ho ur s p rior to the assay , a loop f ul of the 
bac t e ria was trans f e rre d to 25 ml o f ste rile uu t rient broth, 
Dacto Antibiotic Me diwn #2b and incuba t e d a t 37°C for 24 hours . 
On t h e clay of the a ss::ty, ag<J.r plates we r e p r e pare d by 
aSchl e l c h e r a nd Schuell , Inc. , Keen e , NH. 03431 . 
bDifco Labor atories , Detroit, MI . 
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plpetting 25 ml of ilncto Antibiotic Me dium #la into s t e rile 
d isposable polystyrene, 100 x 1 5 mm, petri di s hes .b 
Each of the agar plates was innoc ul a t e d with 0.1 ml of 
broth containing the organ ism. The i nnoc ulum was spread over 
the agar u s ing a s terile cotton s wab a nd allowe d to dry . Five 
absorbent di scs were placed equ idistant on t h e dri e d agar 
s urfaces of the innocul a t e d p e tri dis hes . Predetermined 
vo lumes of the sample so lutio ns were app lie d t o the discs using 
a Micropettor pipette. c The volume-3 u sed were 50 microliters 
of cephalothin ( 20 mcg jml) and gent amicin (10 mcgjml). The 
plates were t h e n incubated for 24 hours at 37°C . Zones of 
inhibi t ion we r e measured with a F i s her -Lilly Antibiotic Zo ne 
Reade r.d 
At t est time, aliquots were t aken from each of the con-
tainers at the various time i.nterva J.s and dilut e d to t he eo:c--
rect assay concentra tion . These dilut i ons were then applied 
to the paper discs . 
Cont rols con sisted of the antibiotic solu tion .·sto re d in 
the glass c ont a iner as well as t h e 5% dextrose inj ection s olu-
tio n alon e appli ed to the paper discs . Following the incuba-
tio n period, the diameters o f the zon es of inhibit ion were 
compared with those obtaine d with g l ass control solutions 
fo r determinat i o n of di ffe r ences . 
aDifco Laboratories , Detroit, MI. 
bKimble , Divi s i o n o £ Owens- Illinois, Toledo, OH. 43666. 
cSc i e nti:f ic Manufact uring Indus tries, Emeryville, CA. 9 '.1:608 . 
dFi s he r Scientific Compa ny,Pittsburg , PA . 
CHAPTER III 
RESULTS 
Beer's Law plots for each of the drugs in 5% dextrose 
injection are shown in Graphs 1-6. These graphs indicate 
the absorbance at ~max as a function of the concentrat ion. 
Figures l through 7 represent the results of the spectro-
photometric a nalysis of each of the drug substances in the 
experimen tal containers . The solutions were examined at 0, 
l, 12, and 2 £! hours. By .:~omparing the s tandard spect~rum and 
the spe ctrum obtat ned in the glass con ta :; 1~ 0:.:.·, t t would have 
been possible to det e rmine the presence of a d~ug-plastic 
interaction if it might have occurred. · 
Any alterations in the peak height, shift in the ~max , 
s hape of the spectrum or the development of secondary peaks, 
was considered to indicate the presence of a drug-plastic 
interaction between the drug solution and the plastic con-
tainer . By comparing the standard spectrum and the spectrum 
of the drug in glass with the spectrum obtained after each 
time interval, it is possible to detect drug-plastic jnter -
actions b etween the drug solution and the container. 
By using Beer's Law plot for each of the drugs, it would 
be possible to determine the concentration loss or amount of 
drug involved in the interaction r eaction. A concentration 
25 
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loss of 10% or greater would be considered a s i gnificant 
loss o:f potency of the drug ( t17 ). 
The d r ug solutions were examine d by UV s p ec troscopy. 
Dilutio n s of the therapeutic co ncentration wer e necessary to 
p roduce UV spectra in the des ired r ecorder range. The con-
centrat ion used appears in the l egend below each of the 
figures and was determined us ing the Beer's La w plot fo r 
e a c h drug. 
The T·nsults o f the UV examination of each drug solution 
in each of the plas tic containers d id not ind icate the pres -
e n ce of a drug - plas ti c interaction . All of the d rug s olutions 
app (:)ared t ·o b e compatible with each of the experime ntal changes 
in any of the UV spectra recorded . 
Followi ng t he procedures outline d i n C~apter II , each 
drug solut ion contai ning a n a ntibiotic was a ssayed micro-
biologically to d e termi.ne the loss of po t.ency. The r esults 
of the microbiological assay are r epresente d in Tables 4 
through J. l which l ist t he diameters of the zon es of inhibition 
of Sta~hylococc us a ureus a nd Stal?hy l ococcus epic!_~_rmid~.s. The 
r esult s were comp ared to a solution containe d wit h i n glass 
at 0, 1, 12, and 24 hours ; a s i gn i fic a nt increase or decre a se 
in zone s izes r epresenting a loss in potency. 
Stati stical evaluation, to determine if a significant 
change occurred i.n ?.one s i ze , was p e r forme d us i ng t he " Student 
t" test . Results of the calculations are found <)n Tab l es '.J.2 
and 1 3 . 
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Analysis of the microbiological assay indicated tltat 
there wer e no significant differences in the antibiotic solu-
tions stored in glass containers a 11d those Gtored in any of 
the plastic containers. 
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1:'i1\ VELENG1rH , NANOt·1E'l'ED.S 
Fi gL:re 3 . U . V . s p e ct r um of i'-'ie t hyldopate; 
1 0 mc .•:) ml , ()..max 2G?. n m) in 5% De xtrose 
Ji: jection at o, 1, 1. 2, <'..n d 24 hour-~ s t ored 
i n the t:: X.!)Crlrr.cntal conta iners . 
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Graph 3 . Beer plot for Methyldopate 
in 5% Dextrose Inject i on . 
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?:.;.~ure 4. U . V . spectr um of T'-Tethotrcxa t8, 
S mcz/ir.l, (,\max 304 nn1) in 5% Dextrose 
TPjection nt o , 1, 12 , and 24 hours sto:-ed 
in the expcr:Lt!l(~ ntal cont< .. d.ncrs . 
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G!'aph 4. D<::er p l ot :l'or r:;ethotre:x.:-.:.te 
in 5% Dextrose Injection . 
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Figure 5 . U.V . spectrum of Dopamine, 
lG mc;::;/ml, ()..max 283 nr:~ ) in 5% Dextrose 
Injcc t:i.on n. t: 0, 1 , 12, and 24 hours stored 
in t:hc t'~.:<pc:r-:i.mcn t a l conta j_ners 
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Graph 5 . Bee r plot for Dopamine 
i n 5% Dextrose Injection . 
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FiEurc G. U. V . spec t rum o:f Gc:ntnmici!:, 
80 mcg/ml , O.:n;~ x 257 nr.1) in 5% Dextrose 
In j cct:i..o n at; o, 1 , 1 2, <mel 24 },ours sto r ed 
in ti1t~ i~xperimentnl c ontnincrs . 
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Graph 6 . Beer plot for Centc.micin 
in 5% Dextrose InjecU.on . 
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'rll\ VEJ.J\NnTH , TJANOi'·TF'rEHS 
Fi.c;ure 7 . li . V. Spectr·um of Cephalothin~ 
20 mc~/ml, (),max 241 nm) in 5% Dextrose 
Injection at 0 , 1 , 12 , and 24 hours stored 
in tllc <·~ Xpl~~·inl8nl;al contain(-.:rs . 
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Graph 7 . Beer pJ.ot fo r CC!)i1Pt l oth.i.n 
in 5% Dextrose Injection. 
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G1ess 
25.0 
26 .0 
? . -
-'..0 
24.2 
26.2 
~- ' £.::>.~ 
26.t. 
25 .0 
27 .0 
25 .2 
26.2 
26.0 
25.0 
23.2 
26.0 
:c=25 .96 
!_0.97 
PS - (POLYSTYR~NE) 
PC - (~GLYCA~BONATE) 
TM3LE 4 
INHIBITION OF GRmiTH OF STAF:-lY! .. OCOCCUS EPI DERN IDIS SY GEN";"AMICIN, 
10 mcg/:n1, IN DEXTROS E 5% IN HATER FOR 0 HOURS STORED It\ TtiE 
EXPER!1:.ENTl\L CONTAINERS 
Zor.es of Ir.hibitio~ {~) 
PS PC LOPE I!UPE PVC-N PVC- \4 PVC- V 
25.4 ;o . 1 25.0 27.0 27.9 26.6 25 .5 
25 .0 25.0 28.0 26.4 :::5 .4 25.7 27.6 26 . 9 26 .1 27.9 25.9 26.9 26.4 26 . 9 26.8 L4 .3 26.8 26.8 27.2 25.3 26.3 25 .2 26.6 25 . 2 26, ,8. 28 .1 26.8 ·27 .8 26.3 26.4 2t, .o 25. 0 27 .0 24. 6 28 .3 27. 8 25 .0 26.3 26.5 26.4 26.6 25.3 26. 0 26.8 25.5 25.0 25 .6 27.6 2G .O 27 .2 2G. 5 28. 0 25.5 23 .3 2'i .6 25.5 2G.S 28.0 25.0 2~.9 26 . 4 25 .6 28.3 2" ~ 2~ . 8 26. 3 26.0 28.4 25 .0 25 .9 v.O 26.4 24.5 26.5 25. 4 2G. 5 28.0 25.0 27. 8 24.5 27.4 29.0 25. 8 26. 9 26.3 
26.0 26.0 26 .8 26.5 t.:5.9 28.8 25.8 
26.0 28.0 27.0 25.6 27 .G 27 . 3 26.3 
x~26.65 x=25.05 x=25 . 45 x=26. 55 ;.:=?.6.65 x=26 . 46 x=26 .66 
+0.97 +1. 19 +1. 16 :!:_] • J 1 T1 . 18 + 1. 21 +0.99 
LOPE: - (LOH- DENSITY POLYETHYLENE) 
HOPE - (H!GH- DENSlTY ?OLYETt~YLENE) 
PVC -N - (PCLY YiNYL CHLOR ID~ -NALGE~E) 
PVC- ~! - (POLn1INYL CHLORI G£- \·:I!Eft.TCH) 
PVC ·V - (POLYVINYL CHLORID[- YI,~FLEX) 
??- N PP- W P!<? 
26.4 26.4 27 .2 
28 . 4 26.2 25 . 6 
25.6 26.0 26.2 
28 .0 26.0 2·1. 0 
26 .2 27.1 2G.2 
25.9 27.2 27. 3 
25 . 8 26 .8 26 . 3 
2G.:; 26.8 25.0 
25 .0 27 . 0 2:3:6 
27.3 27.0 '27 . 8 
213 .6 26.5 26.3 
26. 4 26.8 25 .0 
25 .5 26.5 26.9 
26.0 27 .0 28.0 
26.4 26.8 26.3 
x=26 .70 X"26.65 x=25.51 
+ 1 .01 2:1. 20 +1. 24 
PP- r: - (POLYPRD?YL: rE - HALG:!:E) 
PP-H - (POLYPHOPYLE:iE- i!i!EII'TOH) 
PHP - (POLYI-:ETHYLPE1!TENE) w :_,, 
G1ass 
27.5 
25.4 
26. 5 
27.6 
2·1. 9 
26.5 
?- -
- => . :> 
29.0 
25. 9 
2~ . 6 
25.8 
?' 0 
- O•J 
?- c 
-. O .v 
25.8 
25.~ 
x=25 . 59 
+1 . 12 
PS - (POLYSTYRE~E) 
i'C - ( 1'0!.. YCfliGOr~~\TE} 
I. 
TABLE 5 
INHIBITION OF GRO:HH OF STAPP.YLOCOCCUS EPIDER~liOIS BY GENTANICIN , 
10 mcg/ml , !N DEXTROSE 5% iN HJ\1 ER FOR 1 HO UR STORt:D li'i THE 
EX?ERI :':!:NTAL CO!Ht\lN!:RS 
Zones of Ir.hibitior. (~~; 
?S PC L!'WE HUPE PVC-N PVC- \·1 PVC-V 
26 .9 26 . 2 27.2 27 . 4 2i' .4 2C:.6 28. 3 
26.5 28. 0 26.3 27.6 26.6 26.9 26.3 26.6 28.3 24.2 26. 0 26 .0 26 .0 27.2 
25.0 26.9 26.3 2S.9 25.8 25.3 27.6 
2~.9 26.5 26.1 25,6 26 .0 25.0 26.3 23.6 24 .5 27. 2 25 . 5 25.7 25.6 25. 0 
24.0 2e.o 25.6 26. 9 2!:>.0 23 .8 2~ .3 
2~ . 0 26.5 27.9 25 . 6 26.0 26 .5 25.6 
Zii . 5 26.3 27.3 23.6 26 . 4 23.6 26.9 2tl. 3 26.3 29.3 28 .0 26 . 7 26.3 26.7 26.9 25.8 26. 3 28.0 26.0 28.3 26.4 26 .8 26.8 26. 5 25 .3 ?r. :: 25.6 26.3 ... ..; • J 26 .8 26.6 26.5 24.5 23 .6 26.9 25.6 26 .0 26.3 26.5. 26 .9 23. 6 26.3 25.9 26.0 26.9 26.8 25. 13 ?.b.3 23 .6 25. 9 
x=26.33 x=26.73 x=26 . 67 x=26.31 x=25 .93 x=25 .82 x=26.30 
+1.40 .:_0.91 +L 12 +1 . 24 +1.52 + l .34 + l. 02 
LDPE - (LOW - DENSITY POLYETHYLENE) 
HOPE - (i!IGII- DENSITY POLYETl!YLEN£ } 
PVC-N - (POLYVINYL CHLORIDE-NALGENE) 
PIJC- \4 - (POLYViNYL CH!.. OHIDE-H!!EATG:~ ) 
?Vc~v - (POLYVINYL CH!..ORIDE-VIAFLEX) 
??-!'\ PP- W P1·? 
27 . 5 26.4 26.2 
27 .6 26 . 3 29.0 
25 .9 Z5 . 3 26.9 
26.9 25.3 27. I 
26.5 26.3 25.2 
26.0 24.5 2S .O 
26.3 215 . 5 25.0 
20.5 26 . 8 2G.O 
25.4 n.o 2o:o 
26. 4 27.0 23. 5 
'25.0 25.0 26.3 
23 .9 26 .9 24 . 2 
26.0 26 .8 25.3 
26.0 26.8 26.9 
26.e 26 .9 23 . 5 
x=26 . 23 x=26 .39 x=25 . 27 
+0 . 50 .:!:_0.69 + 1.44 
PP-N - (POL YPKOPYLEriE- Nf\LGEiiE ) 
PP- \·1 - (POL Yf'RO?YLEtiE -~!!!£1\TOtl} 
P~iP - (PO!.. Y:·D!!YLP£tH£t;£) w 0 
I ~ -~' I 
Gias s 
25 . 9 
Z5.S 
27.6 
25 .5 
26.9 
25 .0 
26 . 9 
27 .6 
25 .5 
25.5 
25.9 
25 . 3 
23.2 
2 ~ . 3 
25.9 
x=26 . 46 
.:!:.0. 96 
PS - (POLYSTYRENE) 
?C - (PGLYCA~BONATE) 
Tf.G LE 5 
!NHI3!TION OF GRO\HH OF ST/1PHY LO COCCUS i:P IDERi·~IDIS GY GENTA!"ICIN , 
10 mcg/ml , IN DEXTROS E 5% IN WATER FOR 12 HOURS STORED IN TilE 
EXPERI~lENTl\L CONTJl.IN ERS 
Zones of Inhibition (~m ) 
PS p-. l. LOPE HOPE PVC- N PVC-W PVC-V 
27.5 26 .6 28.0 25.9 2& .4 26.6 25 .0 
?.7 . 4 27.4 26 .5 26.9 25 .0 26 . 0 26.4 
28 .5 26.3 26.9 26.9 27 .9 26.6 26.7 
26.~ 26. 5 23.0 26 . 4 26 . ~ 27.6 27.4 
26 .9 27.0 25.6 26 .2 . 26.0 26. 5 ·26.4 
25. 0 27.0 2•1 . 9 z1:o ... ~ - 26 .0 25.6 ~:>.o 23.9 26 .3 23.9 25.8 27 . 3 26 .0 27 . 0 
28 .0 26 .8 28 . 3 26 .9 26.0 28.3 25 . 5 23 .5 ?.7 . 1 28 .3 25.8 25.6 27 . 1 26 . 8 26 .3 26.4 25.5 26.5 26 .8 26 . 8 25 .2 24.9 27.2 29 .3 28.5 29.5 25.6 27.2 25.8 2'" r 26.8 2!1 .0 27.4 26.0 26.5 :>.o 26. 3 25 . 9 26 .0 26.5 26 .8 25.0 26.9 
25.5 23 .0 25.0 24. 2 25.9 25 .9 26 .0 
26.3 29.0 25.0 ?.7.0 26 .3 27 . 8 25 .0 
x=26.59 x=26 . 61 x-=26.67 x=25.34 x=26. G6 x-=26 . 65 x=26 . 37 
+1.33 .:!:.1 . 25 . .:::_1. 50 .:!:_1. 04 
.!.: . 1'5 !_0 . 78 :::_o. 7o 
LOPE - (LOI-! - OENS ITY POL Y::THYLENE) 
!lOPE - {IIJGH - OENSITY POLYETHYLENE) 
PVC-~ - (PQLYVINYL CiiLORIOE- NALGENE) 
?VC- W - U'OLYV ! NY ~ C!I LOR !DE- \-!!iEATON) 
PIJC- V- (POLY VINYL CH!..ORID£ - VIJI.FLEX) 
P?-N PP-W p;.:p 
26.4 26.5 24.2 
27 .4 26.9 25.2 
25 .6 25.3 25 .3 
27 .2 26 .8 26 .0 
26 . 5 ~6 . !:i 26.5 
26 .5 25.0 ~6.5 
27 . 9 25 .0 zt..o 
26.8 26.9 2:, . e 
26.5 23.6 ze :~ 
27 .o 26.3 "27 . 3 
25.6 ~6.0 2u.5 
27 . 2 26.0 <::6 . e 
26 . Y 25.0 25.8 
29 .0 28.0 21.0 
26 . 5 26 .2_ z6.e 
x=25.~7 x=26.42 x=26. 27 
+C.SS .:::_1. 00 + l . 21 
PP- N - (PO!.. ':'PROPYLENE -!:,;LGE!;E) 
PP- l·/ - (?CLYPROPYL£1'1£ -',:f!U..iO::) 
Pl·iP - (POLY!·HiiYLPEilTEiiE ) w ~ 
Gl ~S·S 
26.2 
26.8 
25 . 0 
23. 0 
27.9 
26.9 
23.0 
28.0 
26 .5 
.... . " l.\: . V 
27 . 3 
28 .6 
27.3 
('!.3 . 2 
26.3 
x=27. i9 
.!_0.95 
PS - ( ?0!.. Y<;JYRE::E) 
?C - (PC!. YC:I!\uO::ATE) 
-- r· I 
T1,.SLE 7 
!NH!BITION OF GROWTH OF STAPHYLOCOCCUS E?IOERM!DIS DY G~NTAMICIN , 
10 mcg/ml, IN DEXTROSE 5% IN Hf1TER FOR 24 !-!OURS STOR~D IN THE 
EXP ERIME NTAL CONTAINERS 
Zon es of Inhib~ t i on (mT.) 
PS PC LOPE !IUPE PYC- N PVC-W PVC- V 
26 .3 26. 3 26.5 27 .2 27 . 4 25.0 25. 9 
26.0 't.7 . 2 26.6 26.2 213 . 2 '2.7 . Y 26 .8 26 .6 25 .9 26 .5 26 . 2 2!1 . 2 26.7 2/ .4 
'2.7 . 7 28.3 26 .9 27.0 27.7 26 .0 28 .5 26. 4 26 .5 2G .5 26 ,.!3 26 . 9 25.6 . 26.8 
27 .4 ;:5.0 26. 0 2G :2 25 .8 2S. l 27 .2 
26.6 25.6 26.0 25. 1 28.5 26 .9 27.6 
25 .3 27.7 28.0 25. 6 28 .5. 26 .8 25.9 25.0 26.2 29.3 29:0 26 .9 26 . 2 27.6 29 .2 26. 3 25.3 26 .5 26 . 8 27.5 25 .8 26 .2 27.5 28.5 2B .Q 27.0 26.3 2!LO 25.4 27.6 27 .5 25.:J ?.7 . ?. 26.5 27.8 25 .9 27.5 27.6 28 .0 25 .0 26.7 27.7 26.7 27.6 25.3 26.9 ". ') 27 . 9 26. n £. U . v 
.26.6 26.6 29.5 29.0 25 . 1 27.0 26.5 
x=26 .49 x=26.77 x=27. 14 x=26 . 91 x=27 .10 x=26. 81 x=27 .22 
+1 . 04 +0.88 .!_l. 25 .:_l. 16 !_1 .C3 -:_0.75 +0.67 
LOP£ - (Lm-1- 0EI'\SITY POLY ETHYLENE) 
i!OPE - (l!JGH- DENSITY POLYETHYLENE) 
PVC- :~ - (PO!..Y\'INY Ci!LORiDE-Ni\LCif:fiE) 
PVC-H - {POLYV!NY CI!LORIO!AI!IEMON) 
i'VC- V - {POLY V! NY CI! LOR!OL-Vlf1FLL<) 
P?-N PP- W P~·~? 
26 .5 26.7 26.3 
211.0 26.4 27.4 
25.~ 26.4 2" ~ :J,v 
26.6 25.5 24.0 
28.3 25.5 25.8 
2t: .O 26. 3 26.e 
24.0 2, . 4 25 .9 
211.5 26 . 3 28.0 
26.9 26. 8 27~5 
t.6 . 3 27.0 26.5 
26 . 4 26. '} 211 .6 
27.6 26 .0 23.5 
2B.O 26.0 26.8 
26. 5· 26.3 25.4 
26.5 27 . 8 29.0 
x=26.39 x=26.60 x=26.51 
+1.46 +0.69 +1 .54 
PP- N - (POLY PROPYLENE - NALWiE} 
PP- ~1 - ( ?::JL Y !•HOP'fLEIIE - ;.::!Ef, TO:I) 
Pr·!P - (POLY :·:LTl!YLFE:nE:i;~) w co 
j I • 
Gl ~s s 
25. 8 
25.4 
27.2 
26 .5 
26.3 
25 .9 
27.2 
Z9.6 
21~ . 5 
26.3 
26.7 
26.9 
28 .0 
26 .5 
26.8 
x=26 .9l 
,:::.0. 39. 
?S - (PO~YSTY RE~E) 
PC - (?OLYC!\K30N/1TE) 
Ti\~LE 8 
INHIBITiON OF GRO:HH OF STAPHYLOCOCCUS AUREUS BY CE?fiALOTHlN , 
20 ~~g/ml , IN DEXTROSE 5% lN WATE R FOR 0 HOURS STORED IN THE 
EXPERI!~ENTAL CONTidNERS 
Zones of Ir.hibition {!T.;;J} 
PS PC LDPE HD?E PVC-N PYC-\4. . PVC- V 
26.0 29 .3 25.8 25 .3 26.0 26.9 26.9 
27 .3 26 .6 ?~ , ... o . .., 26. 3 26. 8 26.2 26.2 
25.9 24 .6 28.0 25 .6 25.4 23.5 25 .2 
25.6 2'f. 6 26.9 26 . l 25.0 26 . 3 .25 .6 
26.5 27 .9 28.6 28 .3 26.8 23.5 2tJ .5 
24 .9 29 .3 26.4 26.0 27. 2 24.5 25.8 
2S . 3 25 .3 26 .3 26.3 27.2 28.0 28 .6 
26.5 25 .3 t:.b.7 25 .8 26.9 28.0 26.9 
2G.S 25.6 27 .a . 2.7 .5 28.6 26.9 25. 8 
26 .8 211.8 28 .5 25 .5 26 . 3 26.9 26 . 0 
23.1 25 .5 27 . 2 26 .9 27 .7 23 .6 27.0 
25.5 25.3 25 . l 26 .9 26 .3 2!3 .0 26. 2 
25.5 29 . 0 27.2 27.0 25.4 25. 7 28 .3 
25. 3 26 .9 25.3 26 .9 25 .6 26.4 27 .o 
25.9 29 .3 26.5 27 .7 27.2 28.0 26.3 
x=26 . 18 x=26. 64 x=zs.ss xo:25 .68 x=26. 63 x=26 . t.8 x,;26.49 
:!:,1. 20 +0 . 42~ +O .SS :.c. 74 ,:::.0 . 93 +1 . 53 2':_1.05 
LD?E - {LOI{- DENSITY POLYETHYLENE) 
HOPE - (Hlilli- DENSITY POLYETHYLENE) 
PVC-N - !P::JLY V NY CHLORIDE -NALGENE) 
PVC-W - (P0LtV NY CHLORIDE-WHEATON) 
PVC- V - (?OLYY NY CHLORIDE- VIAFLEX) 
PP-N P?:-H ?1~? 
26. 3 25 .3 27.6 
25.3 26 .3 29.5 
25 .2 26 .3 26 .3 
24.4 26 . 2 25 .8 
25.2 26 . 4 26.0 
26. 6 26 .6 26.S 
27 . 0 28.0 25 . 3 
26 .9 26 . 3 27 .5 
28.0 27 .0 2~.5 
26 . 3 26 .3 26 . 5 
27 .9 26 .5 26 . 8 
26. 5 26 . 1 23.6 
27 . 4 25 .3 29 .0 
26 . 8 26 . 5 29 .0 
26 .8 25.7 26 . 5 
x=26. 44 x=26 . 45 x=26 . 78 
+1.03 .:_0.56 .:. 1. 62 
PP-N - (POLY?ROPYLENE- NALGE~E) 
??- ·H - (POLYPROPYLEtlE - ~1!-: ::ATO!l) 
?l'.P - (POL YII.ET!!YL?ENTEI{E) 
u; 
(!) 
I 
II 
I 
Glass 
26 .2 
27 .2 
26 . 8 
28 .0 
25 . 2 
25.7 
29.5 
25.3 
26 .7 
26 .1 
,5.-'l 
28. 3 
26 .9 
25 . 4 
26 . 4 
x=?.5 .S8 
+1 . 03 
PS - (POLYSTYR~NE) 
PC - (POLYCARBC!\ATE) 
TAGLE 9 
IN!-!!BITJOH OF GRC\41H OF STAPHYLOCOCCuS 1\URE:US [3':' CEPHJ\LOlT!Df~ 
20 mcg/ml , IN DEXTROSE SY. IN 'ti.t\TER rOR l ~OUR STORED IN THE 
EXPER!i'lEtf:J\L CC:ntdNERS 
Zones of Inh ibi t1on (mm) 
PS PC LDPE HOPE PVC- N rvc-w. PVC- V 
---
27.0 26 . 6 26.4 26 . 9 26.8 2G.6 26.9 
26.5 26 . 5 26 . 5 25.8 25.8 26.5 26.3 
27.2 26 . 8 27 .2 26 .0 26 .2 23.0 27.3 
26.3 27 . 7 25 .0 26 .2 26 .3 26 . 5 26 . 1 
25 .0 26 .7 29 .6 26.3 26. 0 26.3 26.5 
26.3 28.0 26.3 27 .2 27 .2 26.1 26 .1 
24 . 5 26.4 24 .5 26.8 26 . 3 27 .6 27 . 7 
29.3 26 .3 23 .5 26 .5 ?.:' . 4 26.8 25.6 
26.5 27 .3 27.2 2G.4 25 .0 26.!) 24.5 
26.4 26 . 4 25.8 25.0 25.0 24 .9 28 .9. 
26.2 27.8 26 . 5 27 . 7 26 .5 25 .8 ?" 0 _ o . J 
25.7 27 .8 26 .8 27 . 1 20 I' .., .,· 25. 3 26.5 
27 . 5 28 .0 26.8 25 .0 2C .8 25 .1 25 .9 
23 .6 26 .9 26 . 5 27.2 26.£ 25 .9 26 .3 
29 . 3 26 .5 28 . 3 26 .3 2/.2 28.3 25.3 
x=26.38 x=26 .83 x=26.95 Jt=25 .95 x=2o .E3 x=26 . 55 x=26.69 
+1 . 70 +0 . 89 .:_1. 30 +0. 56 .:.o. 98 +0 .87 .+1.18 
LOPE - (L0\·1-DENSITY POLYETHYLENE) 
HOPE - (HIGH- DENSITY POLYETHY LE NE) 
PVC-N- {POLYVINYL CHLOi1 IDE - Nf,LGEi\E) 
PVC-:4 - (POLYVINYL CHLOR! DE- l·!HEATON) 
PVC-V - (POL"I'V!:m .. C!!LORID::- V!/\fl£X) 
I . 
PP- N PP:-~! Pl~? 
25 .6 25 . 9 24 .7 
25.2 27.0 26 . 3 
26.2 25 . 5 24 .5 
25 . 1 27.0 25 .7 
25 .7 25 .0 26 .8 
25.7 26 .9 25.8 
26.3 25 .6 22 .6 
28 .3 26 . 3 26.4 
26 .9 25.3 26.3 
27.1 26.4 28 .3 
26 . 5 26.4 25 .6 
26 . fl 26 . 4 26 . 9 
26 . 3 26 . 3 28 . 3 
26 .5 27 . 3 25. 9 
26.3 25 . 8 26.8 
x=26.37 x=26. 34 x=26 . 19 
+0 . 74 +0.56 +1 . 39 
PP- N - (POLYPROPYLEN:: -NALG::NE) 
PP-H - (POLYP RO:'YLENE-r::-!EfiTO:i) 
Pt'.P - ( POLY!1HIIYLPEIHEt~E) 
~ 
0 
I -- I - ' :·' I I 
G1as s 
25.4 
26 .0 
25 . 4 
25 .2 
26 .3 
~G.Z 
, •. <: 
- ::> ~ .., 
26.3 
25.5 
25 . 6 
25.9 
27.0 
25 .5 
2G.4 
25.5 
x=26.11 
+0 .52 
PS - (POLYSTYRE~E) 
?C - (POLY CARSONATE) 
T/lllLE iO 
I NH !!3 I TI CN OF GflO'...!TH OF ST t\PI! 'I LOCGCCUS AUHEUS BY CE PHALOTHIN , 
20 mcg/n:1 , IN DEXTROSE 5% IN 14/\TER FOR 12 HOURS STORED IN THE 
E XP~RINENTi\L CO:!TAINERS 
Zones of Inhibition (~1ml 
PS PC LOPE li DP E PVC-N PYC-W- PVC-Y 
25.3 28.2 25.6 26 .7 25 .7 23 .9 26 .5 
?6 .2 2G . 8 26 . 3 2G .2 26 . /1. 28 .0 26.5 
25. 7 25 .8 26 . 3 25 . 4 26 .3 26 .5 25 . 4 
25. 2 25 .8 28 .5 26 .3 zr. ~ v .::> 26. 0 24. 5 
25 .3 27.0 25 .6 25 . 8 24.2 27.8 2S.5 
26. 9 25.5 25 .7 26 .3 28.3 24 .3 26.9 
2<1 .5 2·~ . ~ 26. 0 26 .5 27 .7 25 .6 26.4 
25.6 26 . 5 25 .7 26 .5 26 .3 25 . 6 21'..5 
26 . 5 26 .3 26 .3 26. 5 26 .3 24 . 1 25. 1 
2~ . 5 25 .5 26 . 4 26 .5 25 .9 26.6 23 . 8 
25.9 28 . 3 25 .9 26 . 4 26.4 26 .3 28.3 
25.8 26 .0 26. 1 28.3 • I ~ "" (. •;. j 22.3 26.3 
26.2 26 .0 26.6 %t1 .6 26.5 26.3 26.7 
26. 0 2G.3 26 .. 6 2:l. 6 26 . 3 25 .5 26.3 
25.6 2G.4 24.5 25.3 i.'S . 3 26 .9 25. 4 
x=25. 83 x=- 26 .43 x=26. 14 x=25.27 ;.;= 25. 51 x=26 . 18 x=26 . 14 
+0. 77 +0 .90 +0.84 +1 . 23 :::_1.02 +1.3~ . + 1. 31 
-LDPE - tW~-DENSITY POLYETHYLENE) 
HOPE - (Hl~I- DENSITY POLYETHYLENE) 
PVC- ~ - POLYVINYl CHLORIDE - NALGEN E) 
PVC-W - POLYViNY L CHLORIDE-~IEATON) 
PVC- V - POLYV INYL CILCRIDE- VIAFLEX) 
PP-N ?P:-W ?~·~? 
26.5 26.0 25.6 
25 .4 25.9 27.2 
26 .5 26.0 26.2 
26. 9 25 .0 25. 9 
25.3 26.7 26.7 
25.3 29.3 27.2 
26. 3 26.5 25 .7 
26. 8 23.7 23.6 
25.3 26.5 25 .2 
24.6 26.5 26.9 
25. 1 26.4 27 .1 
23.8 25.3 26.0 
26. 3 24.9 26 .2 
25 .8 26.9 ?" -_ !,) ,:;) 
26.5 26.4 27 . 2 
x=25 .76 x=26.2C x=25. 43 
+0 . 89 :_1.19 :_0.93 
PP- N - (POLYPROPYLEil£-!li,LGEiiE ) 
PP-W - (POLYPRO?YLENE-W~EATON ) 
PM? - (POLYi~ETI!YLPE:\TE :i £) 
~ 
!--' 
r· I 
--
- ·- - -·~ ' ' . ~ 
Glass 
. 
27 .6 
25.8 
26. 7 
26.4 
26.5 
25.8 
26 .9 
2t. . 7 
28. 5 
25.7 
25 .0 
26 . 3 
25.0 
27 .3 
25.7 
x=26 .53 
:_0 .94 
PS - (POLYSTYRENE} 
PC - (POLYCARBONAiE) 
Tt'\cLE 11 
INHIBITION OF GROWTH OF STA?HY LOCOC CUS J\UHEUS BY CEPflALOTHIN , 
20 :ncg/m1. Iii DEXTROSE 5% IN WHE R FOR 24 HOURS STOR~!) IN THE 
EXP E~Ir1ENTAL CONTAINERS 
Zcnes of !~ hi bi tion (mml 
. F·S PC LOPE HDPE P·VC-N PYC-W . . . . ?VC-V 
-
25.7 27 .5 26.2 26.8 25.2 27.5 25.4 
27.0 27.3 26.6 26 .3 25.8 26.0 2G.4 
26 . 8 26.2 27.1 27 .0 27.4 27.4 26.5 
26.7 26.1 26 .7 25.3 26.5 26 . 8 25.7 
25.5 25. 9 27.0 26 . 4 'L5_7 26.4 27 .6 
26 .5 26 .5 26 . 2 .28 .2 25.6 25.5 26.l 
26.7 26 .0 26 .5 23 .6 26 .9 27.0 26 .7 
26.3 26.0 27.3 2G.O ?.7 .7 25 .8 26.3 
28.3 26.7 23 . 1 25.5 26 . 2 .' 26 ..1 25 .9 
25. 5 25.6 26. 2 26 .4 25.2 26 . 4 25 . 4 
26 . 4 25.2 25 . 2 26 . 2 25.4 25.4 27.3 
26.7 26.5 25 .6 25.6 t:s .c 26 .3 26.3 
29.3 26. i 26 .9 25.6 26 .9 27 . 4 26.0 
29.3 26.6 26.1 26.3 25 .5 27 .6 25.0 
25.3 26 .6 ~6.3 26 . 9 26.1 26. 5 26.7 
x=26.83 x=25.91 x=26.67 x=26 .22 x=2S.2E x=26 .76 x=26. 33 
+0. 89 ::.o. 46 +0 . 55 .:!:_1.00 + Cj .. ) . 51 
. :!:0. 63 
LOPE - {L0\·1-DENSITY POLYETHYLENE) 
HOPE - (HIGH-DE NSITY POLYETHY LENE) 
PVC-N - (POLY V ~YL CHLORIDE-NALGENE) 
PVC-W - (FOLYV NYL CHLO RIDE-WHEATON) 
PIC- Y - (P~LYV NYL CHLORICE- VIAFLEX) 
.?P- I'i. ?P:-W PI-\? 
25.8 26.7 25.5 
25.5 25.3 26.5 
27 .2 ?' , _o.o 26.0 
26 .7 26.6 26 . 1 
26.3 26.6 25 . 7 
27. 1 26.3 25.6 
26.3 26. 1 26.7 
27.7 26.0 26.0 
25.4 26 .0 26 .0 
26.5 25 .8 25 .9 
27. 0 26.7 25 . 2 
26.0 27.2 26. 1 
26.3 'L6.3 25.8 
26.2 25.7 26.3 
26.3 26.6 27.7 
x= 26 .43 x=26 .37 x=25 . 14 
::_o. &3· ::_0 .47 +0 . 5~ 
P?-N - (POLYPROPYLENE-NALGE~E) 
PP -W - (POLYPROPYLE~E-WHEATG~) 
?11? - (POL YI~ETHYL?ENTE llE) 
~ 
N 
Con·taitler'\ 
PS 
PC 
LD?E 
I-JDP~ 
PVC - I·I 
PVC - '.:! 
PVC- V 
PP- N 
r.) ~)-l·i 
PI.!J) 
PS- (Po,,·~i ·v~e~~) 
• . • ..a.. .) ._, ~ •• ; - "' '-" 
PC- (Po l ycarbonatc) 
TABLE 12 
TIESUI../I'S OF 11 t " VALUT;~ CALCULA'.l'IOHS 
FOR CEPI·IP.LOTHIN , 20 rnce/ml 
(P : 0 . 05 ; n=28 ; t=2 . 048) 
0 hour 1 hour 12 hours 24 hours 
1 . 891 0.974 0 . 959 
0 . 5 63 0 . 142 1 . 194 
0 . 177 0.210 0 . 118 
0 . 769 0 . 222 0 . 695 
0 . 842 0 . 681 1.355 
0 . 941 0 . 947 0 . 189 
1 .174 0 . 469 0 . 083 
1 . 337 1 . 557 1 . 3 15 
1 . 708 1. 724 0 . 2G9 
0 . 252 1 . 5-<·4 1 . 164 
LDPE- ( Lov.r- Dens:L ty ?olyc:thyl(me) 
HDPE- (I-Iizh- Density Polyethylene) 
PVC - N (Polyvinyl Chlori de -r~al[~ene) 
PVC - \'! ( P.:>2. vvinvl Chlori c!e - \·rneaton) 
PVC- V (Polyvinyl Chloride- V:Le.flex) 
0 . 897 
0 . 68 7 
0 . 497 
0 . 875 
0 . 879 
0 . 832 
0 . 684 
0 . 3 42 
0 . 589 
1 . 393 
PP- N ( Pol-ypro1)yleYle - i'Ja l _scne 
PP- v.J (Po l vnroDvlene- \·;hc:>;,d:or..; 
PJ'ijP- (Polyrneti1ylpcntcnc-:) 
,;::. 
w 
I ·-
Cont<?. ine r 
PS 
PC 
LDPE 
f·lDPJ~ 
r'VC- 1"1 
rvc -
'?i!C - V 
PP- N 
PP- \v 
PHP 
PS-
.... ,... 
l:'v -
(Polvstvrene) 
(Pol~ca;Lonate) 
_ _j 
TABLE 13 
RESULTS OF 11 t 11 VALUE CALCULATIONS 
Fo r> ~"''!:"l\,ym .,r,•TCI J••J 1 0 I" C a/ "11 J. \ \...t.L .. d . J.rl. t 1. 1... , ...... 11 w t. -
(P: 0.05; n=23 ; t=2 . 048) 
0 hOU l" 1 hour 12 hours 24 hours 
1. 952 0 .5 622 0 . 397 1 . 913 
0 . 2273 0.3759 0.368 1 . ?.49 
1.2523 0 . 1957 0 . ·457 0.123 
1.5501 1. 500. 0.328 0 . 719 
1.7715 1 . 3522 0 , 516 0 .247 
1. 2506 1.7080 0 . 595 1 . 202 
1. 9524 0 . 7422 0 .293 0 . 00 9 
1 . 964 0 . 9 714 1.239 1. 7 7'J 
1.73 3 0.5892 0 . 112 1.9:i2 
1 . 3518 1 . 528l:. 0 .477 1 , 4SO 
LDPR- ( Low- Density Po lyeth ylene) 
HDPE- (IIit;h- Denf:;:L ty Polyethylr~ ne) 
PVC - N (Polyvinyl Chlori r.le - TJ;:.:. l gcnc) 
PVC- T!.f ( Polyvj_nyl Chlcrj.de -Hhea ton ) 
PVC- V (Po lyvinyl Chloricie - Viaflex) 
PP-N (?o lynronvlene- Nal r.ene) 
... ... Owl -
pP- H (PoJ.:rpropylcne - \·Jheaton) 
PI,iP - (Polyrotr;! thylpcn·cem!) 
~ 
~ 
CHAPTER IV 
DISCUSSION 
The objective of this study was to evaluate different 
plastic containers for pote ntial use as large vol ume paren-
teral containers. Using several types of therapeutic agents , 
solutions of the drugs were s tored in each of the plastic 
containers . The possibility of drug-plastic interactions 
was determined u si.ng spectrophotometric analysis and 
microbiological assay procedures . 
Review of the literature has demons~rated the problems 
that exist with the current types of plastic containers for 
large volume parent e ral solutions. Alth011gh t he curre n t PVC 
preparations offer the advantages of bein g a closed system 
a nd r e quiring no ve11ting , offering the advantages of decreased 
weigh t and storage space , there still exists the problems with 
sorption, leaching, permeation and cl1emical reactivity of the 
drug stored in the PVC formulation. Also importan t is the 
J.ack of rigidity with the PVC containers which presen t s a 
prob l em in handling and ma nipulat ion of t he container . 
Decause of the phys ical nature of PVC, it is necessary 
to add to t h e formulation large amounts of plasticizers, stab-
ilizers, colorants, and othe r materials . The large amounts of 
15 
46 
plasticizer, 20-40% of the finished wei ght of the product, 
impart the flexibility , softness, and clarity required for 
use of the PVC container. It is the large amount of the 
phthalate plasticizer which is the source of potential toxi-
city to the patient infused with a solution from PVC con-
ta:Lners . 
There are several other classes of polymeric materials 
which offer some hope as future large volume parenteral con-
tainers . These non-·PVC polymers offer a h:i.gh tensile strength 
and rigidity than the usual PVC formulations. Such features 
would alleviate some of the problems encountered with handl ing 
and ma nipulation of the container . These polymers are of such 
phyGical properties that they may be formed into devices with-
out the adcU. t ion o :f s i gn if ican t amounts cf pl8.st ieizurs, Gtab·-
ilizers , or other materials. The polymeric materials , nylon, 
polyethylenes, and polypropylenes , are ideal since they are 
ri g id polymers and contain less materials which c ould leach 
from the container . Except for their problems of transparency , 
these polymers present fewer potential toxicological problems . 
Since this study was begun, McGaw Laboratories has mar-
keted a new type of plastic container constructed of poly-
olefin (polyethylene and polypropylene). The composition of 
the container is designed to a lleviate some of the previous 
problems experienced with PVC containers as reviewed in 
Chapter I. 
The present study investigated a number of drugs in solu-
tions s tored in each of the plastic containers . The containers 
l 
47 
were chosen for this study for their potential as containers 
for large volume parenteral solutions. The PVC containers 
were the only containe rs which contaj_ned hi gh amounts of 
l e achable constituents. Rigid PVC containers, s ince they 
contain l ess plasticizers were also include d in this s tudy. 
All the experimental containers offered more r igid i ty than the 
commercially available PVC containers currently used f or 
large volume parenteral solutions. Except for the low-de nsity 
polyethylene and the polystyrene containers, all the other 
containers could b e autoclaved for sterility . While some of 
the containers were trans lucent, manipula·tion o f t he plastic 
formulation could yield transpar ent con tain ers for future 
use as parenteral containers . 
The dr u gs chosen for the st udy were sel e ct e d on the 
b asis of their wide usage as therapeut i c agents in intra-
venous therapy. A wide spectrum of chemical types was . 
se lected for this study. 
The spectrophotometric analysis of the drugs in the 
study indicate d that there were no detect ab l e signs of drug-
plas tic interactions . All of the drug solutions were com-
patible in each of the plastic containers . The UV spectn .. un 
o:f e ach drug examined at 0, 1, 12, and 24 hours showe d no 
signif icant changes when compared to the standard spec trum 
and the spectrurn o btaine d of the drug in the glass container. 
It is interesting to note that the problems with Vitamin 
A experienced by Moorhatch and Chiou (13) were no t e ncount e r e d 
in the course of this s tudy. The y had reported the sorption 
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of 66% of Vitamin A acetate when stored in PVC for 24 hours . 
The differences in results might be accounted for by t he use 
o f diffe rent Vitamin A preparations and so lubil izers used in 
each of the s tudies . Moorhateh and Chiou formulate d their 
own prod.uct using a commercial Vitamin A acetate which the y 
solubilized in aqueous solutions of Tween 80 . This s tudy 
employed Aquasol A, Vitamin A palmitate, solubi liz e d in 12% 
sor ethytan ole ate . 
Although the drugs used i n t his study were fo und to be 
compatible in the containers examined, f urthe r studies are 
nee ded to test other drugs and other intravenous solution 
syst ems . The lack of drug-plastic interactions of t he series 
of drugs tested in thi s s tudy iu no way :i.mplie s t he •.::ornpa.ti-
b ility of all types of d r ugs in the plastic c on t ainers. This 
study offers the possibility of the use of these t ypes of 
plas tj_c containers in place of the existing cotmnercial pro-
ducts now used for large volume parenterals. 
CHAPTER V 
SUMMARY AND CONCLUSIONS 
The purpose of this investigation was to evaluat e severa l 
types of plastic containers for potential use as large volume 
parentera l c ontainers . Drug solutions were examined in each 
of the containers through the use of spectrophotometric anal-
ysis and microbiological assay. The UV absorption spectrwn 
was obtained for each drug solution at 0, J., 1 2, 24 hours 
after storage. The spe ctra obtained were compared to the 
standard speclrum and the spectrum obtaine d fo r the solution 
stored in the glass control container. 
Of the seven drug substances stored J.n the eleven plas-
tic containers, there was no evidence of drug-plastic inter-
actions. While the results indicate the possible utility 
of new types of plastic containers, further work must be 
done to include more drugs in drug-plastic compatibility 
stndies . 
In conclusion, it has been shown with the use of spectro-
photometric analysis a nd microbiological assay that it is 
possible that other materials may be used for the fabrication 
of large volume parenteral containers. The need fo r alterna-
tive types of plastics for use in large volume parenterals 
has been shown in the literature. The results of this study 
49 
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offer some information on nlterantive types of plastics which 
in the future could be a new source of containers for large 
volume parenteral solutions . Ultimately, t he plastic con-
tainer deve l oped for pharmaceutical infusion systems s hould 
be a plastic that yi elds a container that i s st~ong, rigid, 
tra ns parent and does not interact with the drug solution. 
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